Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination Therapy in Glaucoma/Ocular Hypertension
NCT01284166Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Jul 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of dorzolamide, brimonidine and timolol in Glaucoma and ocular hypertension, sponsored by Allergan. Primary endpoint: Intraocular Pressure at Week 12. Planned start Jul 2013; status: withdrawn.
02
Drugs
dorzolamidebrimonidinetimolol
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT01284166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284166.